Certolizumab pegol for the treatment of Crohn’s disease

Abstract

In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate to severe CD. Certolizumab pegol is an effective and welltolerated therapy both in patients who have already received biologics and in patients who are anti-TNF naïve. Benefits of therapy include a stable dosing regimen, which allows for rapid induction of a clinical response followed by long-term maintenance of response and remission under one fixed dose. Treatment with certolizumab pegol has been shown to improve function and quality of life in patients with CD, and insights into the potential mechanisms by which certolizumab pegol effects a response in CD suggest that this agent may have the potential to slow or even modify disease progression. Early therapy is particularly effective and could help control CD progression and lessen the burden of disease on patients.

From Stealthy Polymersomes and Filomicelles to “Self” Peptide-Nanoparticles for Cancer Therapy

“…One widely explored approach for the past two decades involves attachment of hydrophilic polymers such as PEG. PEG has been conjugated to drugs (32), proteins (33), and antibodies (34), in addition to lipids in liposomes (35), providing some degree of stealthiness to all of the systems. PEG is often used as the hydrophilic block in block copolymers because a wide range of molecular weights are readily available and the resulting assemblies in water display PEG chains on the surface of the nanocarrier that delay the physisorption of serum proteins.…”

Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?

“…There have also been reports that patients with antibodies experience more pain at the injection site and more local reactions than those who do not have the antibodies when using CTZ [77].…”

Current Status and Prospects of Polyethyleneglycol-Modified Medicines

“…Other Substances certolizumab pegol (cIMZIA ® ) is the only PEGylated derivative of antibody on the market. 43) It is a PEGylated Fab′ fragment of a humanized monoclonal antibody against tumor necrosis factor (TnF) alpha for the treatment of crohn's disease and rheumatoid arthritis. In terms of PEGylated oligonucleotides, the PEGylated anti-vascular endothelial growth factor (VEGF) aptamer Pegaptanib (MAcuGEn ® ) is a single strand 28mer oligonucleotide and is currently being marketed for the treatment of neovascular (wet) age-related macular degeneration, an eye disease associated with aging that destroys central vision.…”